Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 1996

View Archived Issues

SKB claims morphinoid derivatives

OT-7100, Otsuka's new analgesic for peripheral pain

NPC-18688 displays long-lasting antihyperalgesic effects in rodents

Adolor aims to advance ADL-2-1294 into clinical trials

BMS antimigraine agent poised to enter clinical trials

Iamin gel in phase I in Japan

Dermatology drugs in the BMS pipeline

Hyal-CT1101 effective in phase III trial

Takeda claims novel carbapenems

FD-501: SS Pharm.'s newest fluoroquinolone

Purpuromycin derivative MDL-63604 shows potential for vaginal infections

Swedish authorities okay Amphocil

Ajinomoto claims antivirals

Fomivirsen clinical data presented at international symposium

CPMP recommends approval of Epivir

Bayer claims anti-HIV agents

Dihydrofolate reductase inhibitors synthesized at Duquesne University

Reticulose inhibits HIV replication by stimulating IFN-gamma production

Unique anti-HIV agents reported

Hisamitsu discloses new cyclooxygenase inhibitor

Nihon Iyakuhin's NSAID research bears fruit

Searle and Yamanouchi to codevelop celecoxib

Positive results reported in AllerVax Ragweed trials

Prograf approved for new indication in Japan, launched in France

MitoExtra enters clinical trials

Topotecan approval recommended

Antiandrogen research at Roussel Uclaf

Mitsubishi in-licenses anti-HER2, will begin clinical evaluation soon

GVAX cleared to enter phase III testing

Preclinical results for DC101 presented at AACR

Repligen terminates rPF4 development agreement

Taisho isolates FD-594 from Streptoverticillium

GBC590 progresses to toxicity testing

ISV-205 research results presented at vision conference

NTE-122: Nissin Foods' ACAT inhibitor

Sanofi Winthrop discovers potent ATP-citrate lyase inhibitor

Otsuka evaluates hypolipidemic agents

MTP inhibitor BMS-201038 in development for hyperlipidemia

Colestimide NDA filing imminent

Three beta3-adrenoceptor agonists in preclinical stage at BMS

Amgen presents NESP

Nicorette OTC availability announced

OTC approval for Nicoderm

Tosoh, Morinaga Milk claim type IV collagen detection system

Neoprobe, Peptor to codevelop peptide analogues for cancer diagnosis & treatment

Athena receives patent protection for ApoE in diagnosis of AD

AntiCancer's HDRA receives patent protection

Metasyn updates on MS-325 progress

Trinity Biotech begins marketing osteoporosis test in selected markets

ISV-900 for diagnosis of glaucoma

OraScan 100% sensitive in detecting oral squamous cell carcinomas

Visipaque approved for marketing in U.S.

SKB reports 5-HT2B/2C antagonists for CNS indications

New 5-HT1D antagonists from Pierre Fabre

TAD-93 in preclinical studies for anxiety

IRI-695 for anxiety and depression

U.S. government claims new antipsychotic compositions

Sigma-opioid ligands from ADIR

Mitsui Seiyaku describes sigma-opioid antagonist

New antidepressants disclosed by Yamanouchi

SIBIA, Salk Institute expand agreement for NAChRs

SIBIA, Ciba-Geigy extend drug discovery agreement

Roche licenses access to LIFESEQ database

Oxford Molecular, Yamanouchi to codevelop ion channel modulators

RMP-7 advances to phase I/II in Europe

SKB receives rights to OraSolve dosage technology from CIMA

VIMRx acquires rights to compounds based on RILON technology

Sunrise Technologies will expand phase II LTK trials

Reorganization at Cambridge Biotech

IMRE changes corporate identity

Phytera to acquire Neptune

Ciba-Geigy & Sandoz shareholders approve merger

Avonex approval imminent

Scopolamine gel available in U.S. for motion sickness

Mediolanum synthesizes AChE inhibitors for Alzheimer's

OPC-14523 improves learning in preclinical models

Lilly claims mGluR antagonists for neurodegeneration

NMDA/glycine-site antagonists revealed by RPR

Promising clinical results reported for CRF

Update on terfenadine carboxylate progress

New antiasthmatic drugs patented by Fujirebio

Nikken Chemicals claims new antiasthmatic compounds

Taisho's erythromycin A derivatives suppress IL-5 production

Merck Frosst's new generation of 5-LO inhibitors

TAC-363 pharmacological profile presented

New Glaxo Wellcome compounds protect against leukocyte-induced tissue damage

ACE/NEP inhibitors claimed by Fujisawa

BMS's ACE/NEP inhibitors in phase I

Tanabe Seiyaku investigates ET antagonists

Z-6568 in development at Zambon for cardiovascular disorders

PC-286 lowers blood pressure in rats

Novel vasodilator MCC-134 reported by Mitsubishi Chemical

CP-060S suppresses myocardial cell calcium overload

Banyu's BR-1022 for angina

FR-168888 shows myocardial protective effects in animals

Kanebo reveals new Na+/Ca2+ exchange inhibitor

BMS-191095 in phase I for ischemia

Antirestenosis agents reported by Fujisawa, Teijin

GP-531 enters phase II

Class III antiarrhythmic presented by Japanese academics

BMS-193884 in development for heart failure

Japanese investigators reveal new agent for heart failure

NOS inhibitors claimed by Ono

Genelabs develops two oral antithrombotics

Terumo presents two new fibrinogen receptor antagonists

SR-48692 claimed for use as diuretic

5alpha-Reductase inhibitors for BPH disclosed by Lilly

Enadoline claimed for treatment of BPH

Byk Gulden claims agents for H. pylori control

Amgen initiates phase I trials with KGF

Sanwa's SKK-47029 for disorders of gastric emptying

Infergen NDA filed in U.S.

EPC-K for pancreatitis

Tanabe Seiyaku reports CCK-A antagonist for pancreatitis

OT-5226: New antidiabetic from Otsuka

Pulmonary insulin enters phase II

V-411 approved for marketing in China

MM-218 selected for development in emesis, diarrhea

Dainippon reports anti-H. pylori compounds

IGG completes preclinical testing of MMS1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...